JPWO2020196736A1 - - Google Patents

Info

Publication number
JPWO2020196736A1
JPWO2020196736A1 JP2021509576A JP2021509576A JPWO2020196736A1 JP WO2020196736 A1 JPWO2020196736 A1 JP WO2020196736A1 JP 2021509576 A JP2021509576 A JP 2021509576A JP 2021509576 A JP2021509576 A JP 2021509576A JP WO2020196736 A1 JPWO2020196736 A1 JP WO2020196736A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509576A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020196736A1 publication Critical patent/JPWO2020196736A1/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021509576A 2019-03-28 2020-03-26 Pending JPWO2020196736A1 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019064443 2019-03-28
PCT/JP2020/013623 WO2020196736A1 (ja) 2019-03-28 2020-03-26 ＲＮＡｉ分子

Publications (1)

Publication Number Publication Date
JPWO2020196736A1 true JPWO2020196736A1 (enExample) 2020-10-01

Family

ID=72611078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509576A Pending JPWO2020196736A1 (enExample) 2019-03-28 2020-03-26

Country Status (5)

Country Link
US (1) US20220170022A1 (enExample)
EP (1) EP3950005A4 (enExample)
JP (1) JPWO2020196736A1 (enExample)
CN (1) CN113677373A (enExample)
WO (1) WO2020196736A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517452A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＢＣＬ２遺伝子発現のＲＮＡ干渉媒介性阻害
JP2009540857A (ja) * 2006-06-26 2009-11-26 サントル レジオナル ド ルッテ コントル ル キャンサー−サントル フランソワ バクレシー Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
JP2016539127A (ja) * 2013-11-22 2016-12-15 ミナ セラピューティクス リミテッド Ｃ／ｅｂｐアルファ組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
US20080261905A1 (en) 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
US20060166920A1 (en) * 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
CN106177955B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
JP2019064443A (ja) 2017-09-29 2019-04-25 トヨタ紡織株式会社 乗物用シート
CN113038956A (zh) * 2018-12-05 2021-06-25 日东电工株式会社 癌处置用RNAi分子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517452A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＢＣＬ２遺伝子発現のＲＮＡ干渉媒介性阻害
JP2009540857A (ja) * 2006-06-26 2009-11-26 サントル レジオナル ド ルッテ コントル ル キャンサー−サントル フランソワ バクレシー Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
JP2016539127A (ja) * 2013-11-22 2016-12-15 ミナ セラピューティクス リミテッド Ｃ／ｅｂｐアルファ組成物及び使用方法

Also Published As

Publication number Publication date
CN113677373A (zh) 2021-11-19
US20220170022A1 (en) 2022-06-02
EP3950005A4 (en) 2023-03-29
WO2020196736A1 (ja) 2020-10-01
EP3950005A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
BR112019017762A2 (enExample)
BR112021017339A2 (enExample)
BR112021018450A2 (enExample)
BR112021017637A2 (enExample)
BR112021017892A2 (enExample)
BR112021017782A2 (enExample)
BR112021017939A2 (enExample)
BR112021017738A2 (enExample)
BR112021008711A2 (enExample)
BR112019016141A2 (enExample)
BR112021017728A2 (enExample)
BR112021018452A2 (enExample)
BR112021017703A2 (enExample)
AU2020104490A5 (enExample)
BR112019016142A2 (enExample)
BR112019016138A2 (enExample)
BR112021017732A2 (enExample)
BR112021017355A2 (enExample)
BR112021018168A2 (enExample)
BR112021018093A2 (enExample)
BR112021018102A2 (enExample)
BR112021018250A2 (enExample)
BR112021018584A2 (enExample)
BR112021017310A2 (enExample)
BR112021013128A2 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240611